FDA's Draft MDUFA VI Commitment Letter: What It Means for AI and Digital Health

August 4, 2026 - 21:56

On July 7, the FDA released its draft commitment letter for the sixth iteration of the Medical Device User Fee Amendments, known as MDUFA VI. This document sets the framework for how the agency will fund and run its device review operations from fiscal years 2028 through 2032. Under the MDUFA system, medical device companies pay user fees, and in exchange, the FDA agrees to hit specific performance targets for review timelines and other metrics.

The draft letter carries particular weight for developers of software as a medical device, AI-enabled tools, and other digital health products. For the first time, the FDA is proposing dedicated performance goals for certain types of software submissions, including those that involve machine learning and algorithms that can change over time. The agency is also signaling a push toward more predictable review cycles for SaMD, or software as a medical device, with a focus on shorter, more defined timeframes for decisions.

Another notable element is the proposed expansion of the FDA's digital health expertise. The letter includes plans to hire additional staff with specialized knowledge in AI, cybersecurity, and real-world data analysis. This is a direct response to the growing volume of submissions that rely on complex algorithms and continuous learning models, which often do not fit neatly into traditional device review pathways.

The draft also touches on post-market monitoring for AI products. The FDA is proposing new pilot programs that would allow for more efficient collection of real-world performance data after a device hits the market. This could lead to faster identification of safety issues and more streamlined pathways for updating algorithms without requiring a new submission each time.

Industry stakeholders have until early August to submit comments on the draft. The final commitment letter will be sent to Congress later this year, and the new fee structure is expected to take effect on October 1, 2027. For digital health companies, the message is clear: the FDA is building a review system that treats AI and software as core, not peripheral, parts of its workload.